Changes in Vitamin D Levels in Patients With Systemic Lupus Erythematosus: Effects on Fatigue, Disease Activity, and Damage
|
|
- Bernard Singleton
- 6 years ago
- Views:
Transcription
1 Arthritis Care & Research Vol. 62, No. 8, August 2010, pp DOI /acr , American College of Rheumatology ORIGINAL ARTICLE Changes in Vitamin D Levels in atients With Systemic Lupus Erythematosus: Effects on Fatigue, Disease Activity, and Damage GUILLERMO RUIZ-IRASTORZA, 1 SUSANA GORDO, 2 NEREA OLIVARES, 3 MARIA-VICTORIA EGURBIDE, 3 AND CIRIACO AGUIRRE 4 Objective. To analyze whether changes in serum 25-hydroxyvitamin D (25[OH]D) levels affect activity, irreversible organ damage, and fatigue in systemic lupus erythematosus (SLE). Methods. We performed an observational study of 80 patients with SLE included in a previous cross-sectional study of 25(OH)D, reassessed 2 years later. Oral vitamin D 3 was recommended in those with low baseline 25(OH)D levels. The relationship between changes in 25(OH)D levels from baseline and changes in fatigue (measured by a 0 10 visual analog scale [VAS]), SLE activity (measured by the Systemic Lupus Erythematosus Disease Activity Index [SLEDAI]), and irreversible organ damage (measured by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index [SDI]) were analyzed. Results. Sixty patients took vitamin D 3. Mean 25(OH)D levels increased among all treated patients ( 0.044), in those with baseline vitamin D levels <30 ng/ml ( < 0.001), and in those with baseline vitamin D levels <10 ng/ml ( 0.005). Fifty-seven patients (71%) still had 25(OH)D levels <30 ng/ml and 5 (6%) had 25(OH)D levels <10 ng/ml. Inverse significant correlations between 25(OH)D levels and the VAS ( 0.001) and between changes in 25(OH)D levels and changes in the VAS in patients with baseline 25(OH)D levels <30 ng/ml ( 0.017) were found. No significant correlations were seen between the variation of the SLEDAI or SDI values and the variation in 25(OH)D levels ( 0.87 and 0.63, respectively). Conclusion. Increasing 25(OH)D levels may have a beneficial effect on fatigue. Our results do not support any effects of increasing 25(OH)D levels on SLE severity, although they are limited by the insufficient 25(OH)D response to the recommended regimen of oral vitamin D 3 replacement. INTRODUCTION Vitamin D is a hormone implicated in calcium homeostasis, with additional effects on other organs and systems such as the muscles, endothelium, and immune cells (1). Apart from effects on bone metabolism, vitamin D deficiency has been related to an increased risk of cardiovascular disease and a higher risk of all-cause mortality in the Dr. Olivares s work was supported by Actelion and BIOEF. 1 Guillermo Ruiz-Irastorza, MD, hd: Hospital De Cruces, Barakaldo, and University of the Basque Country, Bizkaia, Spain; 2 Susana Gordo, MD: Hospital General Universitario Gregorio Marañon, Madrid, Spain; 3 Nerea Olivares, MD, Maria-Victoria Egurbide, MD, hd: Hospital De Cruces, Barakaldo, Bizkaia, Spain; 4 Ciriaco Aguirre, MD, hd: University of the Basque Country, Bizkaia, Spain. Address correspondence to Guillermo Ruiz-Irastorza, MD, hd, Servicio de Medicina Interna, Hospital de Cruces, Bizkaia, Spain. r.irastorza@euskalnet.net. Submitted for publication October 5, 2009; accepted in revised form March 1, general population (2). Also, an increased risk for autoimmune diseases, including type 1 diabetes mellitus, multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus (SLE), in relation to low vitamin D levels and/or intake, has been reported (3,4). In the case of lupus, vitamin D deficiency has been advocated as one of the causes explaining the increased prevalence and severity of SLE among African Americans (5). However, the relationship between vitamin D levels and the clinical course of SLE is still controversial. Between January and December 2006, we performed a cross-sectional study including 92 patients from the Lupus-Cruces cohort in whom serum 25-hydroxyvitamin D (25[OH]D) levels were measured. Our results showed a high prevalence of vitamin D insufficiency and deficiency that was related to sun avoidance. A relationship between vitamin D deficiency and fatigue, but not with lupus activity or irreversible organ damage, was found (6). Thereafter, patients were treated with oral vitamin D 3 (in the form of tablets containing fixed combinations of calcium and cholecalciferol or with calcidiol in liquid 1160
2 Vitamin D in SLE 1161 form) at the discretion of the attending physician. After 2 years of therapy and clinical followup of our patients, we aimed to further define the role of vitamin D in modulating the clinical expression of SLE. ATIENTS AND METHODS Design and aims of the study. We designed a longitudinal observational study with the objective of analyzing whether changes in 25(OH)D levels relate to changes in SLE activity, irreversible organ damage, and fatigue. Specifically, we aimed to prospectively confirm our previous results, with the hypothesis of an improvement in fatigue following the increase in 25(OH)D levels. atients. The 92 patients from the Lupus-Cruces cohort that were included in our previous study (6) were contacted and invited to participate in this second, longitudinal part of the study. Eighty patients were available for clinical evaluation during the 2 months (October and November 2008) in which the study took part. All of the patients fulfilled at least 4 of the American College of Rheumatology (ACR) classification criteria for SLE (7) and signed the informed consent form. The local institutional review board approved the study protocol and the informed consent form (study code CEIC E07/38) in compliance with the Helsinki Declaration. Study variables. At the time of signing the informed consent form, the following variables were recorded for this study: age, sex, ethnicity, disease duration, smoking status, current treatment for SLE (prednisone and dose, hydroxychloroquine, immunosuppressive drugs), and the dose and duration of treatment with oral vitamin D 3 since the previous study (maximum 24 months). The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score (8) and the Systemic Lupus International Collaborating Clinics/ACR Damage Index (SDI) score (9) were calculated at that point. In addition, each patient was asked to reflect the degree of fatigue using the same 0 10 visual analog scale (VAS) used in the previous study (where 0 no fatigue and 10 intense fatigue) (10). Levels of 25(OH)D were determined using the Liaison 25OH Vitamin D Total Assay (DiaSorin), as previously described (6). This is a competitive 2-step chemiluminescence assay, with a measuring range of ng/ml. The reported analytical sensitivity is 1.0 ng/ml and the functional sensitivity is 4.0 ng/ml. The reported specificity is 104% for 25(OH)D 2 and 100% for 25(OH)D 3. The reliability of this assay in our laboratory has been regularly assessed by participating in the Vitamin D External Quality Assessment Scheme, the largest vitamin D quality assurance program worldwide (11). Statistical analysis. Herein, we designate T1 as the time when the previous study was done in 2006, and T2 as the time of the current evaluation in October and November The clinical assessment of patients was done at T1 by GR-I and M-VE and at T2 by GR-I and SG. The adherence to treatment with oral vitamin D 3 was addressed by the patients self-reporting. We analyzed whether the 12 patients unavailable for this longitudinal part of the study were different from the remaining cohort in terms of the variables measured at T1. The proportion of patients who achieved optimal levels of 25(OH)D at T2, i.e., at or above 30 ng/mg, was calculated. Likewise, we calculated the proportion of patients with 25(OH)D levels below 20 ng/ml and 10 ng/ml at T2. The variations in 25(OH)D levels, the VAS, and the SLE- DAI and SDI scores between T1 and T2 were analyzed. The relationship between vitamin D and the final clinical variables (fatigue, activity, and damage) was analyzed using 2 different strategies. First, we assessed the association between 25(OH)D levels and each of the corresponding scores (VAS, SLEDAI, and SDI), all measured at T2. Second, we tested the correlation between the changes in 25(OH)D levels and the changes of each of the scores from T1 to T2. Subgroup analysis according to baseline (i.e., at T1) levels of serum vitamin D and according to whether or not treatment with oral vitamin D 3 was received was also performed. The normality of continuous variables was established by means of the Kolmogorov-Smirnov test. According to normality, continuous variables were summarized by the mean SD or the median and range. Univariate comparisons between nominal variables were done by chi-square test with Yates correction or Fisher s exact test, as appropriate. Comparisons of continuous variables between 2 groups were done using a Student s 2-tailed t-test in the case of normal variables and the Mann-Whitney U test in the case of non-normal variables. Variations in variables between T1 and T2 were analyzed using McNemar s test, the Student s paired t-test, or Wilcoxon s test, as required. The associations between continuous variables were tested by linear regression. Adjustment for potential confounders was performed by means of multiple linear regression. All of the statistical calculations were done using SSS software, version , for Mac OS X (SSS). RESULTS Demographic and SLE-related variables. Eighty patients, 72 (90%) of them women and 78 (98%) of them white, agreed to participate in the study. The mean SD age at the time of inclusion was years. The median disease duration was 9.5 years (range 2 29 years). Sixtyseven patients (84%) were taking hydroxychloroquine, 44 (55%) were taking prednisone at a median dosage of 2.5 mg/day (range 0 15), and 16 (20%) were receiving immunosuppressive drugs at T2. The clinical characteristics of the study group at T1 and T2 are shown in Table 1. atients lost to followup. Twelve patients (13%) included in the first study group were not available for a second clinical and biochemical evaluation within the 2 months in which this study was performed. No significant differences in the baseline variables at T1 were found
3 1162 Ruiz-Irastorza et al Table 1. Clinical characteristics of the study group (n 80) at T1 and T2* T1 T2 Female sex 72 (90) 72 (90) N/A Age, mean SD years N/A Disease duration, median (range) years 8 (0 27) 9.5 (2 29) N/A hotosensitivity 54 (67) 54 (67) N/A Anti-Ro antibodies 31 (39) 31 (39) N/A Renal disease 23 (29) 23 (29) N/A rednisone 42 (52) 44 (55) 0.8 rednisone dosage, median (range) mg/day 2.5 (0 10) 2.5 (0 15) 0.7 Immunosuppressive drugs 13 (16) 16 (20) 0.45 Hydroxychloroquine 66 (82) 67 (84) 1.0 Smoking 20 (25) 23 (29) 0.45 SLEDAI score, median (range) 0 (0 18) 2 (0 21) SDI score, median (range) 0 (0 5) 0 (0 6) (OH)D level 30 ng/ml 62 (77) 57 (71) (OH)D level 20 ng/ml 38 (48) 26 (33) (OH)D level 10 ng/ml 13 (16) 5 (6) 0.06 VAS for fatigue, mean SD * Values are the number (percentage) unless otherwise indicated. T1 previous study (2006); T2 current study (2008); N/A not applicable; SLEDAI Systemic Lupus Erythematosus Disease Activity Index; SDI Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; 25(OH)D 25-hydroxyvitamin D; VAS visual analog scale. No patients in this cohort developed renal disease between T1 and T2. between active and missing patients, except for a clinically irrelevant difference in the SDI score (data not shown). Effects of therapeutic intervention. Sixty patients (75%) in the entire group took oral vitamin D 3 for a median period of 24 months (range 7 24 months). Among the 62 patients with 25(OH)D levels 30 ng/ml at T1, 47 (76%) took vitamin D 3 at a median dosage of 800 IU/day (range 400 1,200) during a median period of 24 months (range 5 24 months). Ten (77%) of 13 patients with 25(OH)D levels 10 ng/ml at T1 received oral vitamin D 3 at a median dosage of 600 IU/day (range 400 1,200) for a median period of 24 months (range 7 24 months). Mean 25(OH)D levels of the entire cohort increased from 21.7 ng/ml at T1 to 24.8 ng/ml at T2 ( 0.044). The same was true for patients with 25(OH)D levels 30 ng/ml at T1 (from 16.6 to 23.6 ng/ml; 0.001) and for patients with 25(OH)D levels 10 ng/ml at T1 (from 6.4 to 20.1 ng/ml; 0.001). A significant increase in 25(OH)D levels was seen only among patients who took oral vitamin D 3 (Table 2). Despite the significant increase in mean 25(OH)D levels at T2, it is noteworthy that as many as 57 patients (71%) still had vitamin D levels 30 ng/ml, 26 (33%) had 25(OH)D levels 20 ng/ml, and 5 (6%) had 25(OH)D levels 10 ng/ml (Table 1). Among patients with 25(OH)D levels 30 ng/ml at T1 who took oral vitamin D 3, 34 (72%) did not accrue optimal levels, with 13 (27%) and 2 (4%) patients in this subgroup having 25(OH)D levels 20 ng/ml and 10 ng/ml at T2, respectively. Only 2 of 10 treated patients with 25(OH)D levels 10 ng/ml at T1 attained optimal levels at T2, with 4 (40%) and 2 (20%) of them still having 25(OH)D levels 20 ng/ml and 10 ng/ml, respectively. Relationship between 25(OH)D levels and fatigue. Fatigue improved in the entire cohort according to the reduction seen in the mean SD VAS score between T1 and T2 ( versus ; 0.015) (Table 3). However, an improvement in VAS score was seen only among patients who took oral vitamin D 3, although the differences in the subgroups of treated patients with 25(OH)D levels Table 2. Levels of 25(OH)D at T1 and T2 by subgroups of patients* Subgroup 25(OH)D level at T1, mean SD ng/ml 25(OH)D level at T2, mean SD ng/ml Total cohort (n 80) Total cohort, treated (n 60) Total cohort, untreated (n 20) (OH)D level 30 ng/ml at T1, treated (n 47) (OH)D level 30 ng/ml at T1, untreated (n 15) (OH)D level 10 ng/ml at T1, treated (n 10) (OH)D level 10 ng/ml at T1, untreated (n 3) * 25(OH)D 25-hydroxyvitamin D; T1 previous study (2006); T2 current study (2008). atients who took oral vitamin D 3. atients who did not take oral vitamin D 3.
4 Vitamin D in SLE 1163 Table 3. Variations in the VAS for fatigue according to 25(OH)D levels at T1 and treatment with vitamin D 3 * Subgroup VAS at T1, mean SD VAS at T2, mean SD Total cohort (n 80) Total cohort, treated (n 60) Total cohort, untreated (n 20) (OH)D level 30 ng/ml at T1, treated (n 47) (OH)D level 30 ng/ml at T1, untreated (n 15) (OH)D level 10 ng/ml at T1, treated (n 10) (OH)D level 10 ng/ml at T1, untreated (n 3) * VAS visual analog scale; 25(OH)D 25-hydroxyvitamin D; T1 previous study (2006); T2 current study (2008). atients who took oral vitamin D 3. atients who did not take oral vitamin D ng/ml and 10 ng/ml at T1 did not reach the level of statistical significance ( 0.09 and 0.23, respectively), probably due to the lack of power related to the small numbers of patients (Table 3). We found an inverse significant association between 25(OH)D levels and the VAS score at T2 ( 0.001). This relationship was independent of the effect of other variables shown to influence tiredness in our first study, such as age, SLEDAI score, and treatment with hydroxychloroquine ( 0.001). Using different cutoff points for 25(OH)D levels at T2, the mean SD VAS score was different in those with values above or below 30 ng/ml ( versus ; 0.057), above or below 20 ng/ml ( versus ; 0.001), and above or below 10 ng/ml ( versus ; 0.2). Changes in the VAS score between T1 and T2 were not associated with changes in 25(OH)D levels in the entire cohort ( 0.41). However, a significant inverse correlation was found after restricting this analysis to patients with 25(OH)D levels 30 ng/ml at T1 ( 0.017). The results did not change ( 0.017) after controlling for potential confounders such as treatment with hydroxychloroquine at T2, dose of prednisone at T2, SLEDAI score at T2, SDI score at T2, SLEDAI score variation between T1 and T2, and SDI score variation between T1 and T2, none of which was statistically related to variations in the VAS score. Relationship between 25(OH)D levels, disease activity, and irreversible damage. Regarding the relationship between 25(OH)D levels and disease severity, we obtained results akin to our previous study. Serum levels of 25(OH)D at T2 did not correlate with either SLEDAI or SDI values ( 0.5 and 0.3, respectively). Likewise, median values for both the SLEDAI and SDI did not significantly differ whether the patients had 25(OH)D levels below or above the different cutoff points (Table 4). Both the SLEDAI and SDI scores significantly increased between T1 and T2, although this increase was small in clinical terms (SLEDAI: median 0 [range 0 18] versus median 2 [range 0 21]; 0.015, and SDI: median 0 [range 0 5] versus median 0 [range 0 6]; 0.044). However, no significant association was found between the variation of SLEDAI or SDI values and the variation in 25(OH)D levels between T1 and T2 ( 0.87 and 0.63, respectively). This was also true for the subgroups of patients with 25(OH)D levels at T1 30 ng/ml ( 0.84 and 0.64 for the SLEDAI and SDI, respectively), 20 ng/ml ( 0.58 and 0.64, respectively), and 10 ng/ml ( 0.64 and 0.85, respectively). DISCUSSION In this observational longitudinal study, we have found a high prevalence of suboptimal 25(OH)D serum levels despite therapy with standard doses of oral vitamin D 3. Changes in serum 25(OH)D levels were inversely associated with fatigue, as measured using a 0 10 VAS. On the other hand, no relationship was found between absolute values or variations in 25(OH)D serum levels and scores measuring SLE activity (SLEDAI) or damage accrual (SDI). Low serum 25(OH)D levels in patients with SLE have been demonstrated in a number of studies performed in different populations from countries at variable latitudes (6,12 17). Rather unsurprisingly, photosensitivity has been found to predict vitamin D deficiency (6,13). Besides its well-known effects on calcium homeostasis, vitamin D exerts several additional effects. Vitamin D receptors (VDRs) have been found in muscle cells, with a well-recognized relationship between vitamin D deficiency and muscle weakness (3,18), as well as with cardiovascular disease (19). With respect to autoimmunity, the presence of VDRs is protean among immunologic cells, Table 4. Lupus activity and irreversible damage at T2 according to different cutoff points of serum 25(OH)D* SLEDAI Median (range) SDI Median (range) 25(OH)D level 30 ng/ml 2 (0 21) (0 5) (OH)D level 30 ng/ml 2 (0 8) 1 (0 5) 25(OH)D level 10 ng/ml 2 (0 17) (0 5) (OH)D level 10 ng/ml 2 (0 21) 0 (0 5) *T2 current study (2008); 25(OH)D 25-hydroxyvitamin D; SLEDAI Systemic Lupus Erythematosus Disease Activity Index; SDI Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index.
5 1164 Ruiz-Irastorza et al including T and B lymphocytes, macrophages, and dendritic cells (1). An immunoregulatory role of vitamin D has been proposed, with an increased risk of developing autoimmune diseases among vitamin D deficient individuals (20). Moreover, prophylactic treatment with this compound has been advocated by some authors in order to prevent the development of SLE (21). Yet, the specific effects of vitamin D on SLE are far from clear. Four cross-sectional studies found an inverse relationship between 25(OH)D levels and lupus activity, measured by means of the SLEDAI and/or Systemic Lupus Activity Measure (13,22 24). However, other authors have not found such an association (14 17). Our previous crosssectional study did not show any relationship between 25(OH)D levels and SLEDAI scores, either as a continuous variable or taking into account different cutoff points. Moreover, damage accrual, as measured by the SDI, was not associated with vitamin D deficiency (6). It is important to note that 1,25-dihydroxyvitamin D (1,25[OH] 2 D) is the active form of the hormone, which has been shown to inhibit proliferation and differentiation and enhance apoptosis of activated B cells in in vitro studies (14). In one study, it was 1,25(OH) 2 D, but not 25(OH)D, that correlated with SLE activity (14). The fact that this active form of the hormone is not routinely measured due to fluctuations of its serum levels further complicates the interpretation of the clinical effect of vitamin D on SLE activity. Moreover, conversion of 25(OH)D into 1,25(OH) 2 D is reduced by drugs such as hydroxychloroquine as well as by renal disease (3,25). In this study, we offer a dynamic view of the problem. After recommendation to take oral vitamin D 3, which was followed by 75% of patients, the mean serum 25(OH)D levels of our population with SLE increased significantly, although a high number of patients still had values below 30 ng/ml. However, an inverse decrease in SLEDAI values was not found; rather, mean SLEDAI scores increased parallel to 25(OH)D levels between T1 and T2, although with no significant correlation. atients accrued little damage within the study period despite the improvement in vitamin D levels, again without a statistical association between these 2 variables. Therefore, these data confirm our previous results that showed no relationship between 25(OH)D levels and lupus severity, and neither activity nor irreversible damage (6). On the other hand, our previous finding of improved fatigue with higher 25(OH)D levels has now been confirmed prospectively. We found an independent association between 25(OH)D and the VAS score, both as continuous variables. The median VAS was also higher (reflecting more tiredness) in patients with levels below 30 ng/ml, 20 ng/ml, and 10 ng/ml as compared with those patients with levels above these values, although with a lack of statistical significance in the latter comparison, probably due to the low number of patients in this subgroup (n 5). Indeed, in patients with vitamin D levels below 30 ng/ml at T1, increasing 25(OH)D levels were inversely and significantly correlated with a decrease in the VAS score. Therefore, with fatigue being a complex and multifactorial manifestation of lupus, our results confirm a potential role of vitamin D deficiency in SLE. Measuring fatigue in SLE is a difficult task. In 2007, the Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria for Fatigue reviewed the available instruments to measure fatigue in patients with lupus (26). Fifteen different scales were used in 34 studies. More than 50% of the studies used the Fatigue Severity Scale, a 9-item scale with a 1 7 possible score in each item, which was the instrument recommended by the authors. A VAS similar to that used in this study has also been tested in SLE and employed to measure fatigue in other clinical settings (10). This scale was used in our 2006 cohort and again in this study in order to analyze its variations. However, the actual clinical impact of the reduction of fatigue seen in this study is uncertain and our results should be further validated using more accurate instruments. The nonrandomized design of this study also limits our findings. Moreover, although most patients were treated with oral vitamin D 3, with 25(OH)D levels significantly increasing in the cohort, many of them did not reach optimal levels, which constitutes an additional problem. The possible influence of obesity in the final 25(OH)D levels could not be established because we did not calculate the body mass index of our patients. We did not find any association between 25(OH)D levels and the SLEDAI, either in absolute values or in terms of change over time. It is possible that achieving higher final 25(OH)D levels would have resulted in more striking differences in activity. Likewise, larger variations in SLEDAI scores would have resulted in an increased potency of the study. However, even the trends were not suggestive of an inverse association, since both 25(OH)D levels and the SLEDAI increased significantly over time. On the other hand, despite the same limitation of insufficient vitamin D repletion in many patients, a significant and consistent reduction in fatigue was noted parallel to increasing 25(OH)D levels. In summary, this study supports the use of dosages of vitamin D 3 higher than 800 IU/day for lupus patients with vitamin D insufficiency or deficiency. Dose adjustments should be based on monitoring of serum 25(OH)D levels. In the general population, levels above 30 ng/ml are the recommended goal in order to avoid parathyroid hormone activation (3). However, it is not clear whether these are also the optimal levels in patients with lupus. Increasing 25(OH)D levels may have a beneficial effect in reducing fatigue in patients with SLE. The relationship between vitamin D and lupus activity is complex and still poorly understood, needing further studies to clarify the clinical consequences of vitamin D deficiency and repletion. However, our results do not support any improvement of SLE activity following treatment, and subsequent increase of serum 25(OH)D levels, with oral vitamin D 3. ACKNOWLEDGMENT We thank Dr. Mugica for his help in defining the reliability of the 25(OH)D assay in our hospital. AUTHOR CONTRIBUTIONS All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors ap-
6 Vitamin D in SLE 1165 proved the final version to be submitted for publication. Dr. Ruiz- Irastorza had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study conception and design. Ruiz-Irastorza, Egurbide, Aguirre. Acquisition of data. Ruiz-Irastorza, Gordo, Olivares. Analysis and interpretation of data. Ruiz-Irastorza, Gordo. REFERENCES 1. Kamen D, Aranow C. Vitamin D in systemic lupus erythematosus. Curr Opin Rheumatol 2008;20: Melamed ML, Michos ED, ost W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008;168: Holick MF. Vitamin D deficiency. N Engl J Med 2007;357: Cutolo M. Vitamin D and autoimmune rheumatic diseases. Rheumatology (Oxford) 2009;48: Kamen D, Aranow C. The link between vitamin D deficiency and systemic lupus erythematosus. Curr Rheumatol Rep 2008; 10: Ruiz-Irastorza G, Egurbide MV, Olivares N, Martinez-Berriotxoa A, Aguirre C. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford) 2008;47: Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40: Ward MM, Marx AS, Barry NN. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol 2000;27: Gladman DD, Goldsmith CH, Urowitz MB, Bacon, Fortin, Ginzler E, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for systemic lupus erythematosus international comparison. J Rheumatol 2000;27: Verdon F, Burnand B, Stubi CL, Bonard C, Graff M, Michaud A, et al. Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial. BMJ 2003;326: Carter GD, Carter R, Jones J, Berry J. How accurate are assays for 25-hydroxyvitamin D? Data from the International Vitamin D External Quality Assessment Scheme. Clin Chem 2004; 50: Muller K, Kriegbaum NJ, Baslund B, Sorensen OH, Thymann M, Bentzen K. Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus. Clin Rheumatol 1995;14: Kamen DL, Cooper GS, Bouali H, Shaftman SR, Hollis BW, Gilkeson GS, et al. Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev 2006;5: Chen S, Sims G, Chen XX, Gu YY, Chen S, Lipsly E. Modulatory effects of 1,25-dihydroxyvitamin D 3 on human B cell differentiation. J Immunol 2007;179: Carvalho JF, Blank M, Kiss E, Tarr T, Amital H, Shoenfeld Y. Anti-vitamin D, vitamin D in SLE: preliminary results. Ann N Y Acad Sci 2007;1109: Orbach H, Zandman-Goddard G, Amital H, Barak V, Szekanecz Z, Szucs G, et al. Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TA levels in autoimmune diseases. Ann N Y Acad Sci 2007;1109: Thudi A, Yin S, Wandstrat AE, Li QZ, Olsen NJ. Vitamin D levels and disease status in Texas patients with systemic lupus erythematosus. Am J Med Sci 2008;335: Janssen HC, Samson MM, Verhaar HJ. Vitamin D deficiency, muscle function, and falls in elderly people. Am J Clin Nutr 2002;75: Kendrick J, Targher G, Smits G, Chonchol M. 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. Atheroclerosis 2009;205: Cantorna MT, Zhu Y, Froicu M, Wittke A. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 2004;80 Suppl:S Harel M, Shoenfeld Y. redicting and preventing autoimmunity, myth or reality? Ann N Y Acad Sci 2006;1069: Cutolo M, Otsa K. Vitamin D, immunity and lupus. Lupus 2008;17: Martins DC, Kang J, Aranow C, Mackay M, Kamran M, Xie L, et al. The threshold of vitamin D required for optimal immune regulation: implications for patients with lupus [abstract]. Arthritis Rheum 2006;54 Suppl:S Wu W, Rhew EY, Dyer AR, Dunlop DD, Langman CB, rice H, et al. 25-hydroxyvitamin D and cardiovascular risk factors in women with systemic lupus erythematosus. Arthritis Rheum 2009;61: Huisman AM, White K, Algra A, Harth M, Vieth R, Jacobs JW, et al. Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. J Rheumatol 2001;28: Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria for Fatigue. Measurement of fatigue in systemic lupus erythematosus: a systematic review. Arthritis Rheum 2007;57:
Serum 25-hydroxyvitamin D levels in patients with cutaneous lupus erythematosus in a Mediterranean region
OnlineFirst, published on March 19, 2010 as doi:10.1177/0961203309360807 (2010) 0, 1 5 http://lup.sagepub.com PAPER Serum 25-hydroxyvitamin D levels in patients with cutaneous lupus erythematosus in a
More informationVitamin D Status in Patients with Systemic Lupus Erythematosus in Serbia: Correlation with Disease Activity and Clinical Manifestations
ID Design 2012/DOOEL Skopje Open Access Macedonian Journal of Medical Sciences. 2015 Jun 15; 3(2):256-261. http://dx.doi.org/10.3889/oamjms.2015.052 Clinical Science Vitamin D Status in Patients with Systemic
More informationSerum vitamin D in Egyptian patients with systemic lupus erythematous and its association with lupus nephritis
International Journal of Clinical Rheumatology Serum vitamin D in Egyptian patients with systemic lupus erythematous and its association with lupus nephritis Aim: To assess VD levels in serum of patients
More informationAssociation between vitamin D deficiency and disease activity in juvenile idiopathic arthritis
The Turkish Journal of Pediatrics 2014; 56: 626-631 Original Association between vitamin D deficiency and disease activity in juvenile idiopathic arthritis Elif Çomak 1, Çağla Serpil Doğan 1, Arife Uslu-Gökçeoğlu
More informationZeenat Ali, PGY3 Joseph Grisanti, MD June 7 th, 2012
A Randomized Open Label Trial to Evaluate the Efficacy of Different Dosage Forms of Vitamin D in Patients with Vitamin D Deficiency, and the Effect of Food on Vitamin D Absorption. Zeenat Ali, PGY3 Joseph
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION High Impact of Antiphospholipid Syndrome on Irreversible Organ Damage and Survival of Patients With Systemic Lupus Erythematosus Guillermo Ruiz-Irastorza, MD, PhD; Maria-Victoria
More informationCorrelation between Systemic Lupus Erythematosus Disease Activity Index, C3, C4 and Anti-dsDNA Antibodies
Original Article Correlation between Systemic Lupus Erythematosus Disease Activity Index, C3, C4 and Anti-dsDNA Antibodies Col K Narayanan *, Col V Marwaha +, Col K Shanmuganandan #, Gp Capt S Shankar
More informationCommittee Approval Date: May 9, 2014 Next Review Date: May 2015
Medication Policy Manual Policy No: dru248 Topic: Benlysta, belimumab Date of Origin: May 13, 2011 Committee Approval Date: May 9, 2014 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPORTANT
More informationQuality of Life Over Time in Patients With Systemic Lupus Erythematosus
Arthritis & Rheumatism (Arthritis Care & Research) Vol. 59, No. 2, February 15, 2008, pp 181 185 DOI 10.1002/art.23339 2008, American College of Rheumatology ORIGINAL ARTICLE Quality of Life Over Time
More informationEfficacy and Safety of Belimumab in the treatment of Systemic Lupus Erythematosus: a Prospective Multicenter Study.
1. Title Efficacy and Safety of Belimumab in the treatment of Systemic Lupus Erythematosus: a Prospective Multicenter Study. 2. Background Systemic Lupus Erythematosus (SLE) is a chronic, autoimmune and
More informationVitamin D and Inflammation
Vitamin D and Inflammation Susan Harris, D.Sc. Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University Boston, MA Vitamin D Liver 25(OH)D storage form nmol/l=ng/ml x 2.5 Renal 1,25(OH)
More informationVitamin D Deficiency. Decreases renal calcium excretion. Increases intestinal absorption Calcium. Increases bone resorption of calcium
Vitamin D Deficiency Deborah Gordish, MD Assistant Professor of Clinical Internal Medicine Lead Physician Lewis Center Primary Care Associate Division Director General Internal Medicine The Ohio State
More informationOriginal Article. Abstract
Original Article Diagnostic accuracy of antinuclear antibodies and anti-double stranded DNA antibodies in patients of systemic lupus erythematosus presenting with dermatological features Attiya Tareen*,
More informationVitamin D Supplementation for Pain
Vitamin D Supplementation for Pain Christan M. Thomas, PharmD; Peter Campbell, PharmD US Pharmacist. 2015;40(3):43 46. www.medscape.com Abstract and Introduction Abstract Vitamin D, a fat soluble vitamin
More informationDevelopment of SLE among Possible SLE Patients Seen in Consultation: Long-Term Follow-Up. Disclosures. Background. Evidence-Based Medicine.
Development of SLE among Patients Seen in Consultation: Long-Term Follow-Up Abstract # 1699 May Al Daabil, MD Bonnie L. Bermas, MD Alexander Fine Hsun Tsao Patricia Ho Joseph F. Merola, MD Peter H. Schur,
More informationMandana Nikpour 1,2, Murray B Urowitz 1*, Dominique Ibanez 1, Paula J Harvey 3 and Dafna D Gladman 1. Abstract
RESEARCH ARTICLE Open Access Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective
More informationClinical Commissioning Policy Statement: Rituximab For Systemic Lupus Erythematosus (SLE) December Reference : NHSCB/A3C/1b
Clinical Commissioning Policy Statement: Rituximab For Systemic Lupus Erythematosus (SLE) December 2012 Reference : NHSCB/A3C/1b NHS Commissioning Board Clinical Commissioning Policy Statement: Rituximab
More informationDisclosures. Evidence Based Medicine. Infections in SLE and LN Patients. Aim
Serious Infection Rates among Patients with Systemic Lupus Erythematosus Receiving Corticosteroids and Immunosuppressants None Disclosures Candace H. Feldman, MD, MPH 1,2 Linda T. Hiraki, MD, SM, ScD 3
More informationDescription of Study Protocol. Data Collection Summary
AND Evidence Analysis Worksheet Citation Kostoglou-athanassiou I, AthanassiouP, Lyraki A, Raftakis I, Antoniadis C. Vitamin D and rheumatoid arthritis. Ther Adv Endocrinol Metab. 2012; 3(6):181-7. Study
More informationVitamin D and Calcium Therapy: how much is enough
Vitamin D and Calcium Therapy: how much is enough Daniel D Bikle, MD, PhD Professor of Medicine VA Medical Center and University of California San Francisco DISCLOSURE Nothing to disclose 1 RECOMMENDATIONS
More informationVitamin D. Vitamin functioning as hormone. Todd A Fearer, MD FACP
Vitamin D Vitamin functioning as hormone Todd A Fearer, MD FACP Vitamin overview Vitamins are organic compounds that are essential in small amounts for normal metabolism They are different from minerals
More informationThe Endocrine Society Guidelines
Vitamin D and Calcium Therapy: how much is enough DISCLOSURE Daniel D Bikle, MD, PhD Professor of Medicine VA Medical Center and University of California San Francisco Nothing to disclose RECOMMENDATIONS
More informationVITAMIN D AND THE ATHLETE
VITAMIN D AND THE ATHLETE CONSIDERATIONS FOR THE PRACTITIONER Written by Bruce Hamilton, Qatar Vitamin D is a steroid hormone that has previously been given little attention, partially as a result of its
More informationESPEN Congress Prague 2007
ESPEN Congress Prague 2007 Key papers in the field of nutrition Dietitian Geila S Rozen Key Papers in the field of Nutrition ESPEN 2007 Prague Geila S Rozen Clinical Nutrition Dep. Rambam health campus
More informationSystemic Lupus Erythematosus among Jordanians: A Single Rheumatology Unit Experience
Systemic Lupus Erythematosus among Jordanians: A Single Rheumatology Unit Experience Ala M. AlHeresh MD* ABSTRACT Objectives: To study the characteristics of Systemic Lupus Erythematosus in Jordan and
More informationSYSTEMIC LUPUS ERYTHEMATOSUS: CURRENT CONCEPTS AND CLINICAL PEARLS. Dr Sheila Vasoo Consultant Division of Rheumatology NUHS
SYSTEMIC LUPUS ERYTHEMATOSUS: CURRENT CONCEPTS AND CLINICAL PEARLS Dr Sheila Vasoo Consultant Division of Rheumatology NUHS Listen to the Patient Concepts Diagnosis Immunopathogenesis Clinical Pearls Disease
More informationAssociation of the Charlson Comorbidity Index With Mortality in Systemic Lupus Erythematosus
Arthritis Care & Research Vol. 63, No. 9, September 2011, pp 1233 1237 DOI 10.1002/acr.20506 2011, American College of Rheumatology ORIGINAL ARTICLE Association of the Charlson Comorbidity Index With Mortality
More informationResearch Article Association between Serum 25-Hydroxyvitamin D Level and Rheumatoid Arthritis
BioMed Research International Volume 2015, Article ID 913804, 5 pages http://dx.doi.org/10.1155/2015/913804 Research Article Association between Serum 25-Hydroxyvitamin D Level and Rheumatoid Arthritis
More informationVitamin D Supplementation in the Pediatric Rheumatology Clinic
Curr Rheumatol Rep (2011) 13:110 116 DOI 10.1007/s11926-010-0161-7 Vitamin D Supplementation in the Pediatric Rheumatology Clinic Emily von Scheven & Jon M. Burnham Published online: 8 January 2011 # The
More informationVitamin D: Is it a superhero??
Vitamin D: Is it a superhero?? Dr. Ashraf Abdel Basset Bakr Prof. of Pediatrics 1 2 History of vitamin D discovery Sources of vitamin D and its metabolism 13 Actions of vitamin D 4 Vitamin D deficiency
More informationNon-commercial use only
Reumatismo, 2016; 68 (2): 90-96 Real-world experiences of folic acid supplementation (5 versus 30 mg/week) with methotrexate in rheumatoid arthritis patients: a comparison study K.T. Koh 1, C.L. Teh 2,
More informationDBC 25-Hydroxyvitamin D
D I A G N O S T I C S B I O C H E M C A N A D A DBC 25-Hydroxyvitamin D ELISA OVERVIEW The worldwide aging and chronically ill population is increasing rapidly. It is forecasted that the Global Vitamin
More informationPaediatric rheumatology. Hepatitis B vaccination in juvenile systemic lupus erythematosus
Paediatric rheumatology Hepatitis B vaccination in juvenile systemic lupus erythematosus M.B. Aytac 1, Ö. Kasapcopur 1, M. Aslan 3, T. Erener-Ercan 1, F. Cullu-Cokugras 2, N. Arisoy 1 Departments of 1
More informationErythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE
To cite: Merrill JT, Petri MA, Buyon J, et al. Erythrocytebound C4d in combination with complement and autoantibody status for the monitoring of SLE. Lupus Science & Medicine 2018;5:e000263. doi:10.1136/
More informationAssociation between Depressive Symptoms and Vitamin D Deficiency. among Recently Admitted Nursing Home Patients
Association between Depressive Symptoms and Vitamin D Deficiency among Recently Admitted Nursing Home Patients Gotaro Kojima, MD 1 ; Marianne Tanabe, MD 2 ; Kamal Masaki, MD 3 ; G. Webster Ross, MD 4 ;
More informationSerum cystatin C is independently associated with renal impairment and high sensitivity C-reactive protein in systemic lupus erythematosus
Serum cystatin C is independently associated with renal impairment and high sensitivity C-reactive protein in systemic lupus erythematosus C. Chew 1, P.W. Pemberton 2, A. Al-M. Husain 1,3, S. Haque 3,4,
More informationThe Impact of Life Style & Dietary Habits on Vitamin D status Among Young Emiratis. Fatme Al Anouti, Ph.D. Zayed University, Abu Dhabi
The Impact of Life Style & Dietary Habits on Vitamin D status Among Young Emiratis Fatme Al Anouti, Ph.D. Zayed University, Abu Dhabi The Sun-Shine Vitamin Vitamin D is unique because it can be synthesized
More informationObservations on the occurrence of exacerbations in clinical course of systemic lupus erythematosus
112 ORIGINAL Observations on the occurrence of exacerbations in clinical course of systemic lupus erythematosus Reiko Tomioka 1, Kenji Tani 2,KeikoSato 1, Chiyuki Suzuka 1, Yuko Toyoda 1, Jun Kishi 1,
More informationAssociation of anti-mcv autoantibodies with SLE (Systemic Lupus Erythematosus) overlapping with various syndromes
International Journal of Medicine and Medical Sciences Vol. () pp. 21-214, June 211 Available online http://www.academicjournals.org/ijmms ISSN 2-972 211 Academic Journals Full Length Research Paper Association
More informationAchmad Rifa i 1, Handono Kalim 1, Kusworini 2, C. Singgih Wahono 1. Original Article. 32 Indonesian Journal of Rheumatology 2016; Vol 8 No.
Effect of vitamin D supplementation on disease activity (SLEDAI) and fatigue in Systemic Lupus Erythematosus patients with hipovitamin D: An Open Clinical Trial Achmad Rifa i 1, Handono Kalim 1, Kusworini
More informationOriginal Article High prevalence of hypovitaminosis D of patients with autoimmune rheumatic diseases in China
Am J Clin Exp Immunol 2016;5(3):48-54 www.ajcei.us /ISSN:2164-7712/AJCEI0021982 Original Article High prevalence of hypovitaminosis D of patients with autoimmune rheumatic diseases in China Zhao-Hui Zheng,
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testing_serum_vitamin_d_levels 9/2015 2/2018 2/2019 2/2018 Description of Procedure or Service Vitamin D,
More informationVitamin D & Cardiovascular Disease
Vitamin D & Cardiovascular Disease Disclosures None Vitamin D Objectives: Discuss the basics of vitamin D metabolism Discuss the role of vitamin D deficiency in the development of coronary disease Review
More informationBody image in lupus: Is it disease activity, physical function, depression, pain, fatigue, sleep, fibromyalgia or stress?
International Journal of Clinical Rheumatology Body image in lupus: Is it disease activity, physical function, depression, pain, fatigue, sleep, fibromyalgia or stress? Abstract: Patients with systemic
More informationAssessment of Musculoskeletal Pain among Patients with Vitamin D Deficiency
Original article: Assessment of Musculoskeletal Pain among Patients with Vitamin D Deficiency Dr. Devendra Kumar Kundara Junior Specialist (General Medicine), D.B. Hospital, Churu, Rajasthan, India. Corresponding
More informationBone and Mineral. Comprehensive Menu for the Management of Bone and Mineral Related Diseases
Bone and Mineral Comprehensive Menu for the Management of Bone and Mineral Related Diseases Innovation to Assist in Clinical Diagnosis and Treatment DiaSorin offers a specialty line of Bone and Mineral
More informationElevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab
(2016) 25, 346 354 http://lup.sagepub.com PAPER Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab DA Roth 1, A Thompson 2, Y Tang 2*, AE
More informationAddressing Healthcare Disparities in Autoimmune Disease: A Focus On Systemic Lupus Erythematosus in the USA
Addressing Healthcare Disparities in Autoimmune Disease: A Focus On Systemic Lupus Erythematosus in the USA by Halima Moncrieffe, PhD halima.moncrieffe@cchmc.org Center for Autoimmune Genomics & Etiology,
More informationDiscrepancy between Vitamin D Total Immunoassays due to Various Cross-reactivities
J Bone Metab ;22:7-112 http://dx.doi.org/.105/jbm..22.3.7 pissn 2287-6375 eissn 2287-7029 Original Article Discrepancy between Vitamin D Total Immunoassays due to Various Cross-reactivities Jun Hyung Lee,
More informationAssociation of A1c Levels with Vitamin D Status in U.S. Adults: Data from the National Health and Nutrition Examination Survey
Diabetes Care Publish Ahead of Print, published online March 9, 2010 Vitamin D Status and A1c Levels Association of A1c Levels with Vitamin D Status in U.S. Adults: Data from the National Health and Nutrition
More informationWhich outcome measures in SLE clinical trials best reflect medical judgment?
To cite: Thanou A, Chakravarty E, James JA, et al. Which outcome measures in SLE clinical trials best reflect medical judgment? Lupus Science & Medicine 2014;1:e000005. doi:10.1136/lupus-2013-000005 Received
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-INT-24 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-INT-24 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral disturbances in demented patients: an international, multicenter,
More informationFOCUS ON CARDIOVASCULAR DISEASE
The Consequences of Vitamin D Deficiency: FOCUS ON CARDIOVASCULAR DISEASE Vitamin D deficiency is a global health problem. With all the medical advances of the century, vitamin D deficiency is still epidemic.
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A A Diabetes Outcome Progression Trial (ADOPT), 194 Adaptive immunity, 129 131 ADOPT (A Diabetes Outcome Progression Trial), 194 Aging, vitamin
More informationThe Relationship Between Serum 25(OH)D and Parathyroid Hormone Levels
CLINICAL RESEARCH STUDY The Relationship Between Serum 25(OH)D and Parathyroid Hormone Levels Walid Saliba, MD, MPH, a Ofra Barnett, PhD, a Hedy S. Rennert, MPH, a Idit Lavi, MA, a Gad Rennert, MD, PhD
More informationTo estimate the population attributable cancer risk associated with excess salt and
Appendix 1 (as supplied by the authors): Supplementary Material 1: Methods for Population Attributable Cancer Risks for Excess Salt and Insufficient Calcium and Vitamin D To estimate the population attributable
More informationThe importance of vitamin D levels in autoimmune diseases
review article The importance of vitamin D levels in autoimmune diseases Cláudia Diniz Lopes Marques 1, Andréa Tavares Dantas 2, Thiago Sotero Fragoso 3, Ângela Luzia Branco Pinto Duarte 4 ABSTRACT In
More informationBAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008
BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology
More informationSubscale analysis of quality of life in patients with systemic lupus erythematosus: association with depression, fatigue, disease activity and damage
Subscale analysis of quality of life in patients with systemic lupus erythematosus: association with depression, fatigue, disease activity and damage S.T. Choi 1, J.I. Kang 2, I.-H. Park 3, Y.W. Lee 4,
More informationSafety and effectiveness of biologic Disease-Modifying Antirheumatic Drugs in elderly patients with rheumatoid arthritis
1. Title: Safety and effectiveness of biologic Disease-Modifying Antirheumatic Drugs in elderly patients with rheumatoid arthritis 2. Background: The population of older individuals with rheumatoid arthritis
More informationFOR CONSUMERS AND PATIENTS
AVAILABILITY OF VITAMIN D FOR CONSUMERS AND PATIENTS Prof. Heike A. Bischoff-Ferrari, MD, DrPH Centre on Aging and Mobility, University of Zurich Dept. of Rheumatology, University Hospital Zurich Overview
More informationEmerging Areas Relating Vitamin D to Health
ILSI SEA Region Vit D Conference, Australia, June 2012 (www.ilsi.org/sea Region) Emerging Areas Relating Vitamin D to Health Peter R Ebeling MD FRACP NorthWest Academic Centre and Dept Endocrinology The
More informationSelecting the Right Data Analysis Technique
Selecting the Right Data Analysis Technique Levels of Measurement Nominal Ordinal Interval Ratio Discrete Continuous Continuous Variable Borgatta and Bohrnstedt state that "the most of central constructs
More informationAuthor's response to reviews
Author's response to reviews Title:Placebo-Controlled Randomized Clinical Trial of Fish Oil's Impact on Fatigue, Quality of Life, and Disease Activity in Systemic Lupus Erythematosus Authors: Cristina
More informationEastern Paediatric Epilepsy Network
1. Objective 2. Background 3. Vitamin D and epilepsy 4. Monitoring and optimizing bone health in healthy children 5. 6. Recommendations 1.) Objective: 1.1) To provide a rational basis for monitoring bone
More informationUpdate on vitamin D. J Chris Gallagher Professor of Medicine and Endocrinology Creighton University Omaha,Nebraska USA
Update on vitamin D J Chris Gallagher Professor of Medicine and Endocrinology Creighton University Omaha,Nebraska 68131 USA Cali, Colombia 2016 definitions DRIs are the recommended dietary reference intakes
More informationUPDATES ON PEDIATRIC SLE
UPDATES ON PEDIATRIC SLE BY ANGELA MIGOWA, PEDIATRIC RHEUMATOLOGIST/SENIOR INSTRUCTOR AKUHN MBCHB-UON, MMED-AKUHN,PEDIATRIC RHEUMATOLOGY- MCGILL UNIVERSITY HEALTH CENTRE ROSA PARKS OBJECTIVES RECOGNIZE
More informationThe Vitamin D Gap. Vitamin D intake guidelines were established to prevent. Estimating an adequate intake of vitamin D. FEATURE VITAMIN D GAP
The Vitamin D Gap Estimating an adequate intake of vitamin D. By Laurence Montgomery, ND and George Tardik, ND Vitamin D intake guidelines were established to prevent rickets in children and osteomalacia
More informationAuthor's response to reviews
Author's response to reviews Title:The association between lean mass and bone mineral content in the high disease activity group of adult patients with juvenile idiopathic arthritis Authors: Kristyna Brabnikova
More informationJournal of American Science 2014;10(10)
Biomarkers assay for identification and prediction of flare in patients with Systemic lupus Erythematosus Nashwa Noreldin 1 Samah elshweek 1 and Mohamed M. Attia 2 1 Department of Internal Medicine, College
More informationTITOLO RELAZIONE Vitamina D e aspetti immunologici. DOCENTE Michele Miraglia del Giudice
TITOLO RELAZIONE Vitamina D e aspetti immunologici DOCENTE Michele Miraglia del Giudice ????? bone skin placenta adrenal glands Vitamin D Receptors (VDR) are present in different tissues intestine kidneys
More informationVitamin D Deficiency and Reduced Lung Function in Connective Tissue-Associated Interstitial Lung Diseases
CHEST Original Research DIFFUSE LUNG DISEASE Vitamin D Deficiency and Reduced Lung Function in Connective Tissue-Associated Interstitial Lung Diseases Jared T. Hagaman, MD ; Ralph J. Panos MD, FCCP ; Francis
More informationOriginal Article. Elizabeth Kos, MD 1 ; Mary Jo Liszek, MD 2 ; Mary Ann Emanuele, MD 3 ; Ramon Durazo-Arvizu, PhD 4 ; Pauline Camacho, MD, FACE 3
Original Article Elizabeth Kos, MD 1 ; Mary Jo Liszek, MD 2 ; Mary Ann Emanuele, MD 3 ; Ramon Durazo-Arvizu, PhD 4 ; Pauline Camacho, MD, FACE 3 ABSTRACT Objective: To determine the effect of metformin
More information8/6/2018. Glucocorticoid induced osteoporosis: overlooked and undertreated? Disclosure. Objectives. Overview
Disclosure Glucocorticoid induced osteoporosis: overlooked and undertreated? I have no financial disclosure relevant to this presentation Tasma Harindhanavudhi, MD Division of Diabetes and Endocrinology
More informationVitamin D and Calcium
Vitamin D and Calcium American Association of Clinical Endocrinologists Marina Del Rey, CA September 15, 2018 Albert Shieh, MD MS Assistant Clinical Professor Department of Medicine Division of Endocrinology
More informationVitamin D concentrations and disease activity in Moroccan children with juvenile idiopathic arthritis
Bouaddi et al. BMC Musculoskeletal Disorders 2014, 15:115 RESEARCH ARTICLE Open Access Vitamin D concentrations and disease activity in Moroccan children with juvenile idiopathic arthritis Ilham Bouaddi
More informationVitamin D Supplementation During Pregnancy and Infancy Reduces Sensitisation to House Dust Mite: a Randomised Controlled Trial
Vitamin D Supplementation During Pregnancy and Infancy Reduces Sensitisation to House Dust Mite: a Randomised Controlled Trial Cameron Grant, 1 4 Julian Crane, 3 Ed Mitchell, 1 Jan Sinclair, 4 Alistair
More informationIMPACT OF LONG TERM-STEROID TREATMENT PRESCRIBED FOR SYSTEMIC AND AUTOIMMUNE DISEASES ON THE DEVELOPMENT OF ATHEROSCLEROSIS.
1 IMPACT OF LONG TERM-STEROID TREATMENT PRESCRIBED FOR SYSTEMIC AND AUTOIMMUNE DISEASES ON THE DEVELOPMENT OF ATHEROSCLEROSIS. A NETWORK ORGANIZED BY THE EUROPEAN FEDERATION OF INTERNAL MEDICINE Coordination:
More informationFinal published version:
Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort S Sam Lim, Emory University
More informationFIBROMIALGIA: CLASSIFICAZIONE ED EPIDEMIOLOGIA DELLA SINDROME
FIBROMIALGIA: CLASSIFICAZIONE ED EPIDEMIOLOGIA DELLA SINDROME D.A. Filippini S.C. Reumatologia ASST Grande Ospedale Metropolitano Niguarda Milano MALATTIA DOLORE E RETE TERRITORIALE OSPEDALE NIGUARDA MILANO
More informationS. Rinaldi, A. Doria, F. Salaffi 2, M. Ermani 1, L. Iaccarino, A. Ghirardello, S. Zampieri, P. Sarzi-Puttini 3, P. F. Gambari and G.
Rheumatology 2004;43:1574 1579 Advance Access publication 7 September 2004 Health-related quality of life in Italian patients with systemic lupus erythematosus. I. Relationship between physical and mental
More informationImportance of Vitamin D in Healthy Ageing. Peter Liu, B Pharmacy Market Development Manager DSM Nutritional Products Asia Pacific 11 th November 2014
Importance of Vitamin D in Healthy Ageing Peter Liu, B Pharmacy Market Development Manager DSM Nutritional Products Asia Pacific 11 th November 2014 Healthy life expectancy the challenge! Life expectancy
More informationHASHIMOTO S THYROIDITIS NOT ASSOCIATED WITH VITAMIN-D DEFICIENCY
ENDOCRINE PRACTICE Rapid Electronic Article in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited, typeset
More informationRole of BAFF in B cell Biology and Autoimmunity
Role of BAFF in B cell Biology and Autoimmunity B cell development in health and disease: B-lymphocytes or B cells, and the antibodies they produce, are crucial mediators of humoral immunity, providing
More informationAssociation between serum 25-hydroxyvitamin D and depressive symptoms in Japanese: analysis by survey season
University of Massachusetts Amherst From the SelectedWorks of Kalpana Poudel-Tandukar Summer August 19, 2009 Association between serum 25-hydroxyvitamin D and depressive symptoms in Japanese: analysis
More informationANTIMALARIALS IN INCOMPLETE LUPUS ERYTHEMATOSUS SIMULATION STUDY OF AN ONGOING CLINICAL TRIAL
The Pennsylvania State University The Graduate School College of Medicine ANTIMALARIALS IN INCOMPLETE LUPUS ERYTHEMATOSUS SIMULATION STUDY OF AN ONGOING CLINICAL TRIAL A Thesis in Public Health Sciences
More informationLearned helplessness predicts functional disability, pain and fatigue in patients with recent-onset inflammatory polyarthritis
RHEUMATOLOGY Rheumatology 2013;52:1233 1238 doi:10.1093/rheumatology/kes434 Advance Access publication 18 February 2013 Original article Learned helplessness predicts functional disability, pain and fatigue
More informationVitamin D deficiency is associated with longer hospital stay and lower functional outcome after total knee arthroplasty.
Reference number to be mentioned by correspondence : ORTHO/- Acta Orthop. Belg., 2015, 83, 00-00 ORIGINAL STUDY Vitamin D deficiency is associated with longer hospital stay and lower functional outcome
More informationLong-term impact of belimumab on health-related quality of life and fatigue in patients with systemic lupus erythematosus: 6 years of treatment
Article type : Original Article Long-term impact of belimumab on health-related quality of life and fatigue in patients with systemic lupus erythematosus: 6 years of treatment Vibeke Strand 1 (MD, MACR,
More informationVitamin D levels in Indian systemic lupus erythematosus patients: association with disease activity index and interferon alpha
Mandal et al. Arthritis Research & Therapy 2014, 16:R49 RESEARCH ARTICLE Open Access Vitamin D levels in Indian systemic lupus erythematosus patients: association with disease activity index and interferon
More informationFreire EAM *,**,***, Bruscato A ***,****, Leite DRC *, Sousa TTS *, Ciconelli RM **,*** Abstract. Introduction
ARTIGO ORIGINAL TRANSLATION INTO BRAZILIAN PORTUGUESE, CULTURAL ADAPTATION AND VALIDATATION OF THE SYSTEMIC LUPUS ERYTHEMATOSUS QUALITY OF LIFE QUESTIONNAIRE ( SLEQOL) Freire EAM *,**,***, Bruscato A ***,****,
More informationFM CFS leaky gut April pag 1
FM CFS leaky gut April 21 2018 pag 1 FIBROMYALGIA / CHRONIC FATIGUE SYNDROME AND LEAKY GUT. SUMMARY OF CLINICAL TRIAL DESIGN. Double-blind randomized placebo-controlled challenge with gluten and milk protein
More informationImpact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort
Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort S Sam Lim, Emory University Ben Parker, The University of Manchester Murray
More informationFreedom of Information Appeal: design of MHRA-approved First in Man studies, and associated reporting of Suspected Serious Adverse Reactions
Freedom of Information Appeal: design of MHRA-approved First in Man studies, and associated reporting of Suspected Serious Adverse Reactions Sheila M. Bird, MRC Biostatistics Unit, CAMBRIDGE CB2 2SR In
More informationBisphosphonates in the Management of. Myeloma Bone Disease
Bisphosphonates in the Management of Myeloma Bone Disease James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Myeloma Bone Disease Myeloma cells
More informationOsteoarthritis Research Society /98/ $12.00/0
Osteoarthritis and Cartilage (1998) 6, (Supplement A), 31 36 9 1998 Osteoarthritis Research Society 1063-4584/98/030031 + 06 $12.00/0 OSTEOARTHRITIS and CARTILAGE Efficacy and tolerability of oral chondroitin
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testing_serum_vitamin_d_levels 9/2015 2/2017 2/2018 2/2017 Description of Procedure or Service Vitamin D,
More informationBenlysta (belimumab) Prior Authorization Criteria Program Summary
Benlysta (belimumab) Prior Authorization Criteria Program Summary This prior authorization applies to Commercial, NetResults A series, NetResults F series and Health Insurance Marketplace formularies.
More informationARD Online First, published on May 16, 2014 as /annrheumdis Clinical and epidemiological research
ARD Online First, published on May 16, 2014 as 10.1136/annrheumdis-2013-205171 Clinical and epidemiological research Handling editor Tore K Kvien For numbered affiliations see end of article. Correspondence
More informationMedical journals have recently. Vitamin D Defi ciency in Dialysis Patients and Its Effect on Various Disease Markers. Methods
Patients and Its Effect on Various Disease Markers Adel B. Korkor, MD; Christine M. Bretzmann, PharmD; Daniel C. Eastwood, MS Drs. Korkor and Bretzmann are with Purity Dialysis Centers, Delafi eld, Wisconsin;
More information